When one considers the sampling error inherent in taking 1–4 mL of an organ of approximately 3 L total volume15 (0.03–0.12%), it is likely that a much higher percentage of patients with ER+ breast cancer harbor DTCs in the bone marrow. This evidence concerns the gene ESR1 and breast carcinoma.